Complement system causes cell damage in Long Covid


Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of manifestations. The causes and disease mechanisms of Long Covid are still unknown, and there are no diagnostic tests or targeted treatments.

A team of researchers has shown in a study that the complement system plays an important role in Long Covid. It is part of the innate immune system and normally helps to fight infections and eliminate damaged and infected body cells.

“In patients with Long Covid, the complement system no longer returns to its basal state, but remains activated and, thus, also damages healthy body cells,” says the author.

The researchers followed 113 COVID-19 patients for up to one year after their acute SARS-CoV-2 infection and compared them with 39 healthy controls. After six months, 40 patients had active Long Covid disease. More than 6,500 proteins in the blood of the study participants were analyzed both during the acute infection and six months later.

“The analyses of which proteins were altered in Long Covid confirmed the excessive activity of the complement system. Patients with active Long Covid disease also had elevated blood levels indicating damage to various body cells, including red blood cells, platelets and blood vessels,” explains the first author of the study.

The measurable changes in blood proteins in active Long Covid indicate an interaction between proteins of the complement system, which are involved in blood clotting and the repair of tissue damage and inflammation. In contrast, the blood levels of Long Covid patients who recovered from the disease returned to normal within six months. Active Long Covid is therefore characterized by the protein pattern in the blood.

“Our work not only lays the foundation for better diagnosis, but also supports clinical research into substances that could be used to regulate the complement system. This opens up new avenues for the development of more targeted therapies for patients with Long Covid,” summarizes the author.

https://www.science.org/doi/10.1126/science.adg7942

http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fpersistent-complement&filter=22

Rating

Unrated
Rating: